Amgen to Discuss Phase II Sotorasib Data in NSCLC With Regulators

Apr

Oncology in the Time of COVID-19: Quantitative Proteomic Analysis of Anti-IL6 Treated Patients

This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.

Jun

Featured Webinar

Precision Oncology in Melanoma Patients Treated with Immunotherapy: Clinical and Technological Perspective

This webinar, the second in our Next-Generation Proteomics for Precision Oncology series, will discuss how unbiased discovery proteomics can be used to identify new key mechanisms and signatures supporting clinical decision-making for melanoma patients.

Menu

Amgen to Discuss Phase II Sotorasib Data in NSCLC With Regulators

To read the full story....

Breaking News

NCI Director Sharpless Outlines Ideas to Aggressively Lower Cancer Deaths at AACR Annual Meeting

AACR Study Tests Immunogenic Signature in Prostate Cancer Patients on Dual Checkpoint Inhibitor

Celcuity Licenses PI3K/mTOR Inhibitor from Pfizer, Enters $25M Debt Financing Agreement

In Brief This Week: Gilead Sciences, Atossa Therapeutics, Karmanos Cancer Institute

Gene Expression Score IDs PD-1/PD-L1 Immune Checkpoint Inhibitor Resistance in Bladder Cancers

Portage Biotech Begins Phase I Trial of Invariant Natural Killer T-Cell Therapy

Featured White Papers

Oncology in the Time of COVID-19: Quantitative Proteomic Analysis of Anti-IL6 Treated Patients

Precision Oncology in Melanoma Patients Treated with Immunotherapy: Clinical and Technological Perspective

What's Popular?

In Brief This Week: Gilead Sciences, Atossa Therapeutics, Karmanos Cancer Institute

Immunocore's Tebentafusp Prolongs Survival in Uveal Melanoma Patients, AACR Study Shows

Celcuity Licenses PI3K/mTOR Inhibitor from Pfizer, Enters $25M Debt Financing Agreement

With Support From Lawmakers, WGS Becoming More Accessible to Netherlands' Cancer Patients

Gene Expression Score IDs PD-1/PD-L1 Immune Checkpoint Inhibitor Resistance in Bladder Cancers

Sponsorships